JP2004525076A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004525076A5 JP2004525076A5 JP2002527247A JP2002527247A JP2004525076A5 JP 2004525076 A5 JP2004525076 A5 JP 2004525076A5 JP 2002527247 A JP2002527247 A JP 2002527247A JP 2002527247 A JP2002527247 A JP 2002527247A JP 2004525076 A5 JP2004525076 A5 JP 2004525076A5
- Authority
- JP
- Japan
- Prior art keywords
- mutant
- polypeptide
- wild
- therapeutic composition
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000003812 Interleukin-15 Human genes 0.000 description 37
- 108090000172 Interleukin-15 Proteins 0.000 description 37
- 239000000203 mixture Substances 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 14
- 230000001225 therapeutic effect Effects 0.000 description 14
- 108010017535 Interleukin-15 Receptors Proteins 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- 102000004556 Interleukin-15 Receptors Human genes 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- 235000003704 aspartic acid Nutrition 0.000 description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000030833 cell death Effects 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 230000006786 activation induced cell death Effects 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 102000056003 human IL15 Human genes 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
Images
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23225100P | 2000-09-14 | 2000-09-14 | |
| PCT/US2001/028612 WO2002022805A2 (en) | 2000-09-14 | 2001-09-14 | Modulation of il-2- and il-15-mediated t cell responses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004525076A JP2004525076A (ja) | 2004-08-19 |
| JP2004525076A5 true JP2004525076A5 (enExample) | 2008-11-06 |
Family
ID=22872402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002527247A Pending JP2004525076A (ja) | 2000-09-14 | 2001-09-14 | Ｉｌ−２およびｉｌ−１５媒介ｔ細胞応答の調節 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20020114781A1 (enExample) |
| EP (2) | EP1349873B1 (enExample) |
| JP (1) | JP2004525076A (enExample) |
| CN (1) | CN1317301C (enExample) |
| AT (1) | ATE427318T1 (enExample) |
| AU (1) | AU2001292645A1 (enExample) |
| BR (1) | BR0113906A (enExample) |
| CA (1) | CA2422294C (enExample) |
| DE (1) | DE60138222D1 (enExample) |
| ES (1) | ES2322936T3 (enExample) |
| IL (1) | IL154925A0 (enExample) |
| MX (1) | MXPA03002278A (enExample) |
| RU (1) | RU2280255C2 (enExample) |
| WO (1) | WO2002022805A2 (enExample) |
| ZA (1) | ZA200302933B (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7541184B2 (en) | 2000-02-24 | 2009-06-02 | Invitrogen Corporation | Activation and expansion of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US7247304B2 (en) | 2001-08-23 | 2007-07-24 | Genmab A/S | Methods of treating using anti-IL-15 antibodies |
| US20050084967A1 (en) * | 2002-06-28 | 2005-04-21 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| EP2347767A3 (en) * | 2003-01-31 | 2013-06-12 | Albor Biologics, Inc. | Immune regulation based on the targeting of early activation molecules |
| DE602004031341D1 (de) | 2003-07-21 | 2011-03-24 | Transgene Sa | Multifunktionelle cytokine |
| DE602004031681D1 (de) * | 2003-07-21 | 2011-04-14 | Transgene Sa | Multifunktionelle Cytokine |
| US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
| EP1706428B1 (en) * | 2004-01-22 | 2009-09-23 | MERCK PATENT GmbH | Anti-cancer antibodies with reduced complement fixation |
| PL1899364T5 (pl) | 2005-05-17 | 2024-12-09 | University Of Connecticut | Kompozycje i sposoby immunomodulacji w organizmie |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| JP5709356B2 (ja) | 2006-01-13 | 2015-04-30 | アメリカ合衆国 | 哺乳動物細胞における発現のためのコドン最適化ＩＬ−１５およびＩＬ−１５Ｒ−α遺伝子 |
| WO2007124331A2 (en) * | 2006-04-19 | 2007-11-01 | Virginia Commonwealth University | Cardioprotective and other uses of mammalian target of rapamycin (m-tor) inhibitors |
| US20110020269A1 (en) * | 2007-05-08 | 2011-01-27 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for modifying t cell immune responses and inflammation |
| CA2690825C (en) | 2007-05-11 | 2019-02-12 | Altor Bioscience Corporation | Fusion molecules and il-15 variants |
| AU2008269032B2 (en) | 2007-06-27 | 2013-12-05 | Novartis Ag | Complexes of IL-15 and IL-15Ralpha and uses thereof |
| JP2009065938A (ja) * | 2007-09-14 | 2009-04-02 | Matsumoto Shika Univ | タンパク質、破骨細胞分化阻害剤、炎症性骨破壊治療薬、遺伝子、組み替えベクター、及びタンパク質の製造方法 |
| SG173457A1 (en) * | 2009-02-27 | 2011-09-29 | Novartis Ag | Methods for selecting eukaryotic cells expressing a heterologous protein |
| NZ714757A (en) | 2009-08-14 | 2018-07-27 | Us Gov Health & Human Services | Use of il-15 to increase thymic output and to treat lymphopenia |
| CN105017429B (zh) | 2010-09-21 | 2021-04-06 | 阿尔托生物科学有限公司 | 多聚体il-15可溶性融合分子与其制造与使用方法 |
| US11053299B2 (en) | 2010-09-21 | 2021-07-06 | Immunity Bio, Inc. | Superkine |
| WO2015089217A2 (en) | 2013-12-10 | 2015-06-18 | Bionz, Llc | Methods of developing selective peptide antagonists |
| SI2665486T1 (sl) * | 2011-01-18 | 2020-07-31 | Bioniz, Llc | Sestavki za moduliranje aktivnosti gama-C-citokina |
| WO2014005072A1 (en) | 2012-06-28 | 2014-01-03 | University Of Central Florida Research Foundation, Inc. | Methods and compositions for natural killer cells |
| HK1220918A1 (zh) | 2013-04-19 | 2017-05-19 | 赛腾制药 | 降低的血管渗漏综合征的细胞因子衍生治疗 |
| EP2915569A1 (en) | 2014-03-03 | 2015-09-09 | Cytune Pharma | IL-15/IL-15Ralpha based conjugates purification method |
| EP3160498B1 (en) | 2014-06-30 | 2021-10-06 | Altor BioScience Corporation | Il-15-based molecules and methods of use thereof |
| EP3482766B1 (en) | 2014-08-11 | 2020-05-20 | Delinia, Inc. | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| US12233104B2 (en) | 2015-10-08 | 2025-02-25 | Nektar Therapeutics | Combination of an IL-2RBETA-selective agonist and a long-acting IL-15 agonist |
| WO2017062685A1 (en) | 2015-10-09 | 2017-04-13 | Bioniz, Llc | Modulating gamma - c -cytokine activity |
| MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
| US20170157215A1 (en) | 2015-12-04 | 2017-06-08 | Jomoco, Corp. | Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| CN106591368A (zh) * | 2016-10-12 | 2017-04-26 | 郑州大学 | 携带il‑15r/il‑15融合基因的b亚群腺病毒11载体及其构建和用途 |
| WO2018075989A1 (en) | 2016-10-21 | 2018-04-26 | Altor Bioscience Corporation | Multimeric il-15-based molecules |
| CN110167957A (zh) | 2016-11-08 | 2019-08-23 | 德里尼亚公司 | 用于治疗自身免疫疾病的il-2变体 |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CN110753555A (zh) | 2017-04-19 | 2020-02-04 | 得克萨斯州大学系统董事会 | 表达工程化抗原受体的免疫细胞 |
| RU2698048C2 (ru) * | 2017-10-03 | 2019-08-21 | Закрытое Акционерное Общество "Биокад" | МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα |
| EP3755349A4 (en) | 2018-02-21 | 2021-11-17 | Board of Regents, The University of Texas System | PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES |
| WO2020227019A1 (en) | 2019-05-03 | 2020-11-12 | Bioniz, Llc | Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders |
| WO2021050789A1 (en) | 2019-09-10 | 2021-03-18 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
| WO2021222178A1 (en) * | 2020-04-27 | 2021-11-04 | The Trustees Of Indiana University | Adjunct therapy for suppressing immune response against gene therapy |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| CN113209277A (zh) * | 2021-05-17 | 2021-08-06 | 武汉大学 | Neogenin在制备预防、缓解和/或治疗心肌梗死及其相关疾病药物中的应用 |
| CN114773433B (zh) * | 2022-06-23 | 2022-09-06 | 北京肿瘤医院(北京大学肿瘤医院) | 一种cd25靶向多肽、分子探针及应用 |
| WO2024138175A1 (en) * | 2022-12-22 | 2024-06-27 | Forte Subsidiary, Inc. | Methods of treating acute and chronic graft versus host diseases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5011684A (en) * | 1985-09-05 | 1991-04-30 | Beth Israel Hospital Association | Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| EP0567586B1 (en) | 1991-01-16 | 1995-07-12 | Schering Corporation | Use of interleukin-10 in adoptive immunotherapy of cancer |
| IL101353A0 (en) * | 1991-04-03 | 1992-11-15 | American Home Prod | Pharmaceutical compositions for treating diabetes |
| CA2144648A1 (en) | 1992-09-18 | 1994-03-31 | Mario Clerici | Restoration of immunocompetency to t helper cells in hiv infected patients |
| US5574138A (en) * | 1993-03-08 | 1996-11-12 | Immunex Corporation | Epithelium-derived T-cell factor |
| US5747024A (en) * | 1993-03-08 | 1998-05-05 | Immunex Corporation | Vaccine adjuvant comprising interleukin-15 |
| US5552303A (en) * | 1993-03-08 | 1996-09-03 | Immunex Corporation | DNA encoding epithelium-derived T-cell factor |
| IL111004A (en) * | 1993-09-30 | 1998-06-15 | American Home Prod | Oral formulations of rapamycin |
| US5795966A (en) | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
| CA2252557A1 (en) * | 1996-04-26 | 1997-11-06 | Beth Israel Deaconess Medical Center, Inc. | Antagonists of interleukin-15 |
| DE69810091T2 (de) * | 1997-02-21 | 2003-10-09 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw., Zwijnaarde | Verwendung von interleukin-15 |
| DE19823351A1 (de) | 1997-05-16 | 1998-12-10 | Krause Hans | Mittel zur Verhinderung der Zellapoptose bei Krankheiten |
-
2001
- 2001-09-14 CN CNB018185339A patent/CN1317301C/zh not_active Expired - Fee Related
- 2001-09-14 JP JP2002527247A patent/JP2004525076A/ja active Pending
- 2001-09-14 BR BR0113906-1A patent/BR0113906A/pt not_active IP Right Cessation
- 2001-09-14 CA CA2422294A patent/CA2422294C/en not_active Expired - Fee Related
- 2001-09-14 EP EP01973022A patent/EP1349873B1/en not_active Expired - Lifetime
- 2001-09-14 IL IL15492501A patent/IL154925A0/xx unknown
- 2001-09-14 AU AU2001292645A patent/AU2001292645A1/en not_active Abandoned
- 2001-09-14 ES ES01973022T patent/ES2322936T3/es not_active Expired - Lifetime
- 2001-09-14 EP EP09004784A patent/EP2123672A1/en not_active Withdrawn
- 2001-09-14 AT AT01973022T patent/ATE427318T1/de not_active IP Right Cessation
- 2001-09-14 WO PCT/US2001/028612 patent/WO2002022805A2/en not_active Ceased
- 2001-09-14 RU RU2003110571/15A patent/RU2280255C2/ru not_active IP Right Cessation
- 2001-09-14 DE DE60138222T patent/DE60138222D1/de not_active Expired - Lifetime
- 2001-09-14 US US09/953,323 patent/US20020114781A1/en not_active Abandoned
- 2001-09-14 MX MXPA03002278A patent/MXPA03002278A/es not_active Application Discontinuation
-
2003
- 2003-04-14 ZA ZA200302933A patent/ZA200302933B/en unknown
- 2003-12-30 US US10/749,699 patent/US7579439B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004525076A5 (enExample) | ||
| US6579520B2 (en) | IL-17 related mammalian cytokine polypeptides (IL-17E) | |
| US6569645B2 (en) | IL-17 homologous polypeptides and therapeutic uses thereof | |
| EP0888122B1 (en) | HYBRID WITH INTERFERON-alpha AND AN IMMUNOGLOBULIN Fc LINKED THROUGH A NON-IMMUNOGENIC PEPTIDE | |
| CN102665754B (zh) | 衍生自il-2的免疫调节多肽及其在治疗癌症和慢性感染中的用途 | |
| EP1240325B1 (en) | Il-17 and il-17r homologous polypeptides and therapeutic uses thereof | |
| JP2003533488A5 (enExample) | ||
| US20190032134A1 (en) | Interleukin-10 Production of Antigen-Specific CD8+ T Cells and Methods of Use of Same | |
| CA2690399C (en) | Il-6 antagonist peptides | |
| KR20170068553A (ko) | 인터류킨-15 조성물 및 이의 용도 | |
| EP3302547A1 (en) | Pegylated interleukin-10 for use in treating cancer | |
| JP2007267750A (ja) | 可溶性ｉｌ−ｔｉｆ／ｉｌ−２２レセプターまたはｉｌ−ｔｉｆ／ｉｌ−２２に結合する結合タンパク質をコードする単離された核酸分子、およびその使用 | |
| JP2010535488A (ja) | インターフェロン融合タンパク質 | |
| RU2506270C2 (ru) | Пептид-антагонист активности интерлейкина-15 | |
| US20030199044A1 (en) | IL-17 homologous polypeptides and therapeutic uses thereof | |
| EA003942B1 (ru) | Усеченный по амино-концу моноцитарный хемотаксический белок (mcp-2) и способы его использования | |
| Lai et al. | Shared gamma (c) subunit within the human interleukin-7 receptor complex. A molecular basis for the pathogenesis of X-linked severe combined immunodeficiency. | |
| US20030203451A1 (en) | IL-17 homologous polypeptides and therapeutic uses thereof | |
| US20030180255A1 (en) | IL-17 homologous polypeptides and therapeutic uses thereof | |
| CA3180251A1 (en) | Cytokine conjugates | |
| WO2023095913A1 (ja) | ヒトｔｎｆｒ２アゴニストとして利用可能なポリペプチド | |
| WO2016196211A1 (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| KR100308441B1 (ko) | 인터루킨-16활성을갖는프로세싱된폴리펩티드,그의제조방법및용도 | |
| US20030054442A1 (en) | IL-17 homologous polypeptides and therapeutic uses thereof | |
| JP4507084B2 (ja) | アポトーシス誘導性ペプチド及びその利用 |